Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results